公开(公告)号：US12128043B2

公开(公告)日：2024-10-29

申请号：US18602981

申请日：2024-03-12

申请人： INTRA-CELLULAR THERAPIES, INC.

发明人： Peng Li ,  Robert Davis

IPC分类号： A61K31/4985 ,  A61K9/00 ,  A61K9/16 ,  A61K9/48

CPC分类号： A61K31/4985 ,  A61K9/0053 ,  A61K9/16 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4891

摘要： The present disclosure relates to pharmaceutical capsules comprising lumateperone, in free, or pharmaceutically acceptable salt form, optionally in combination with one or more additional therapeutic agents, processes for manufacture thereof and methods of use in the treatment or prophylaxis of disease.

公开(公告)号：US20240343731A1

公开(公告)日：2024-10-17

申请号：US18437153

申请日：2024-02-08

申请人： BIOMEA FUSION, INC.

发明人： Priyanka SOMANATH ,  Daniel LU ,  Taisei KINOSHITA ,  Brian LAW ,  Thomas BUTLER ,  James T. PALMER ,  Nan-Horng LIN ,  Heow Meng TAN ,  Angelina Sau Man WONG ,  Siyi JIANG ,  Hongyan HE

IPC分类号： C07D487/04 ,  A61K9/00 ,  A61K9/48 ,  A61P35/00 ,  A61P35/02

CPC分类号： C07D487/04 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61P35/00 ,  A61P35/02 ,  C07B2200/13

摘要： Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide, including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.

公开(公告)号：US20240325396A1

公开(公告)日：2024-10-03

申请号：US18606590

申请日：2024-03-15

申请人： Allarity Therapeutics, Inc.

发明人： Marie FOEGH ,  Steen KNUDSEN

IPC分类号： A61K31/519 ,  A61K9/28 ,  A61K9/48 ,  A61K31/496 ,  A61P35/00

CPC分类号： A61K31/519 ,  A61K9/28 ,  A61K9/4825 ,  A61K31/496 ,  A61P35/00

摘要： Described are methods of treating cancer (e.g., solid tumor cancer) using stenoparib monotherapy at BID dosing or a combination therapy including stenoparib (at BID dosing) and dovitinib (at QD dosing).

公开(公告)号：US20240325312A1

公开(公告)日：2024-10-03

申请号：US18576218

申请日：2022-07-13

申请人： Incannex Healthcare Limited

发明人： Mark Robert Bleackley ,  Joel Bradley Latham

IPC分类号： A61K9/48 ,  A61K31/00 ,  A61K31/4706 ,  A61P29/00

CPC分类号： A61K9/4808 ,  A61K9/4825 ,  A61K31/4706 ,  A61K31/658 ,  A61P29/00

摘要： The present disclosure relates generally to compositions comprising a synergistic combination of cannabidiol (CBD) or a pharmaceutically acceptable salt or derivative thereof and hydroxychloroquine or a pharmaceutically acceptable salt thereof, which beneficially enables simultaneous administration of the two active pharmaceutical ingredients (APIs) in a single dosage form. In an embodiment, the present disclosure also relates to methods and uses of the composition for the treatment of an inflammatory condition.

公开(公告)号：US20240316075A1

公开(公告)日：2024-09-26

申请号：US18575762

申请日：2022-06-30

申请人： ANANDA SCIENTIFIC, INC

发明人： Mark. J. ROSENFELD ,  Sohail R. ZAIDI ,  Christopher B.G. MOORE

IPC分类号： A61K31/00 ,  A61K9/48

CPC分类号： A61K31/658 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/4875

摘要： Disclosed herein are methods of effectively treating or preventing Pain, chronic non-cancer pain (CNCP), chronic reticular pain, and opioid sparing in subjects utilizing chronic opioid therapy (COT) with pharmaceutical compositions, as well as kits containing the compositions and instructions for carrying out the method.

公开(公告)号：US20240307316A1

公开(公告)日：2024-09-19

申请号：US18605959

申请日：2024-03-15

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College ,  Inha University ,  Baylor College of Medicine

发明人： Jangwook P. Jung ,  Swathi Balaji ,  Myungwoong Kim ,  Carlos E. Astete

IPC分类号： A61K9/48 ,  A61K33/08 ,  A61P17/02

CPC分类号： A61K9/4866 ,  A61K9/4825 ,  A61K33/08 ,  A61P17/02

摘要： In one aspect, the disclosure relates to compounds comprising one or more lignin derivatives, at least one organic peroxide, and a pharmaceutically-acceptable carrier. In an aspect, the one or more lignin derivatives can be or include thiolated lignosulfonate (TLS), sodium lignosulfonate (SLS), or a combination thereof. In one aspect, the SLS can be grafted to a polymer or copolymer such as poly(lactic-co-glycolic) acid (PLGA) in order to form a shell of a core-shell nanoparticle, wherein the shell surrounds a core of the inorganic peroxide and protects the core from premature activation in an aqueous wound environment. In another aspect, the pharmaceutically-acceptable carrier can be a hydrogel forming polymer such as a methacrylated gelatin, which can assist in modulating the properties of the lignin derivatives to be suitable for injection. Also disclosed herein are methods of using the disclosed compositions for the treatment of wounds in subjects, including in diabetic subjects.

公开(公告)号：US20240300950A1

公开(公告)日：2024-09-12

申请号：US18427226

申请日：2024-01-30

申请人： BIOMEA FUSION, INC.

发明人： Satish Goud Puppali ,  James T. Palmer ,  Thorsten A. Kirschberg ,  Angelina Sau Man Wong ,  Heow Meng Tan ,  Jay Li ,  Ming Lin ,  Ming Gao ,  Junlu Ding ,  Shuang Li ,  Yuyao GU ,  Hongyan He ,  Bo Zheng ,  Yanjing Zhou ,  Mei You ,  Yihong Qiu

IPC分类号： C07D487/04 ,  A61K9/20 ,  A61K9/48 ,  A61K31/5377 ,  A61K45/06 ,  A61P3/10 ,  A61P35/02

CPC分类号： C07D487/04 ,  A61K9/2009 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2059 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/5377 ,  A61K45/06 ,  A61P3/10 ,  A61P35/02

摘要： Described herein is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide (Compound A) (Formula I),




including crystalline forms, solvates, and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions or pharmaceutical formulations that include the compound, as well as methods of using the compound, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, diabetes, and inflammatory diseases or conditions.

公开(公告)号：US20240299306A1

公开(公告)日：2024-09-12

申请号：US18437368

申请日：2024-02-09

申请人： CHEMOCENTRYX, INC.

发明人： Manmohan Reddy LELETI ,  Jay P. POWERS

IPC分类号： A61K9/48 ,  A61K31/4412

CPC分类号： A61K9/4858 ,  A61K9/4808 ,  A61K9/4825 ,  A61K9/4833 ,  A61K31/4412

摘要： The present disclosure provides solid solution capsule formulations of Compound 1




and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

公开(公告)号：US12077502B2

公开(公告)日：2024-09-03

申请号：US17871065

申请日：2022-07-22

申请人： PRAXIS PRECISION MEDICINES, INC.

发明人： Kiran Reddy ,  Margaret S. Lee ,  Gabriel Maurice Belfort ,  Sapna Makhija Garad ,  Mahesh Padval ,  Randall Wagner ,  Marion Wittmann

IPC分类号： C07D211/34 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26

CPC分类号： C07D211/34 ,  A61K9/0053 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4825 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/445 ,  A61K47/38 ,  A61P25/14 ,  C07D211/26 ,  C07B2200/13

摘要： Described herein, in part, are dosage forms and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a T-type calcium channel, such as epilepsy and epilepsy syndromes (e.g., absence seizures, juvenile myoclonic epilepsy, or a genetic epilepsy), tremor (e.g., essential tremor), and psychiatric disorder (e.g., mood disorders (e.g., major depressive disorder)). The present invention further comprises methods for modulating the function of a T-type calcium channel.

公开(公告)号：US20240287082A1

公开(公告)日：2024-08-29

申请号：US18611118

申请日：2024-03-20

申请人： Hoffmann-La Roche Inc.

发明人： Giuseppe CECERE ,  Luca GOBBI ,  Steven Paul HANLON ,  Maria-Clemencia HERNANDEZ ,  Roland HUMM ,  Andreas KOBLET ,  Andrés Miguel OLIVARES MORALES ,  Valerie RUNTZ-SCHMITT

IPC分类号： C07D487/04 ,  A61K9/16 ,  A61K9/48 ,  A61K31/5513

CPC分类号： C07D487/04 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/4825 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/5513

摘要： The invention provides novel heterocyclic compounds having the general formula (I), and pharmaceutically acceptable salts thereof, wherein R1 to R5 and X are as described herein.




Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds for the treatment or prevention of acute neurological disorders, chronic neurological disorders and/or cognitive disorders.